Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells 12,380 Shares

by · The Cerbat Gem

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) Director Daniel Allen Gold sold 12,380 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.28, for a total transaction of $436,766.40. Following the sale, the director directly owned 13,689,166 shares of the company’s stock, valued at $482,953,776.48. This represents a 0.09% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Daniel Allen Gold also recently made the following trade(s):

  • On Monday, June 29th, Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock. The stock was sold at an average price of $34.55, for a total transaction of $27,640,000.00.
  • On Friday, June 26th, Daniel Allen Gold sold 625,783 shares of Roivant Sciences stock. The shares were sold at an average price of $34.00, for a total transaction of $21,276,622.00.

Roivant Sciences Stock Up 1.9%

Shares of NASDAQ:ROIV traded up $0.66 during midday trading on Tuesday, hitting $35.39. The stock had a trading volume of 6,160,114 shares, compared to its average volume of 5,917,255. The company’s 50-day moving average price is $29.88 and its 200-day moving average price is $27.02. The company has a market capitalization of $25.45 billion, a P/E ratio of -58.98 and a beta of 1.13. Roivant Sciences Ltd. has a fifty-two week low of $10.70 and a fifty-two week high of $35.90.

Roivant Sciences (NASDAQ:ROIV – Get Free Report) last issued its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. The company had revenue of $2.52 million during the quarter, compared to the consensus estimate of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same quarter in the prior year, the firm posted ($0.29) EPS. Research analysts expect that Roivant Sciences Ltd. will post -1.83 EPS for the current fiscal year.

Institutional Trading of Roivant Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. UBS Group AG increased its holdings in shares of Roivant Sciences by 570.0% during the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock worth $399,080,000 after buying an additional 15,645,836 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Roivant Sciences by 31.7% during the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after acquiring an additional 14,036,696 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Roivant Sciences by 365.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock worth $238,323,000 after acquiring an additional 8,621,567 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Roivant Sciences by 11,507.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock worth $150,535,000 after acquiring an additional 6,877,348 shares during the last quarter. Finally, Norges Bank acquired a new position in Roivant Sciences in the 4th quarter worth about $112,750,000. Institutional investors own 64.76% of the company’s stock.

Analysts Set New Price Targets

ROIV has been the topic of a number of research analyst reports. Leerink Partners set a $42.00 target price on Roivant Sciences in a report on Thursday, May 21st. Citigroup raised their price objective on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, May 21st. Weiss Ratings cut Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Jefferies Financial Group reissued a “buy” rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Finally, Sanford C. Bernstein assumed coverage on Roivant Sciences in a research note on Friday, March 20th. They set an “outperform” rating and a $35.00 target price for the company. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $33.59.

Read Our Latest Stock Analysis on Roivant Sciences

Roivant Sciences Company Profile

(Get Free Report)

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.

Recommended Stories